This study is testing a drug called MIB-626 to see if it's safe and well-tolerated in adults with Down syndrome (DS). The goal is to understand how different doses of MIB-626 affect the body and if it could help prevent or reverse Alzheimer's disease. Researchers will give participants MIB-626 or a placebo (an inactive pill that looks like the study drug) daily for 28 days. They will carefully monitor for any side effects and conduct blood tests and heart checks (electrocardiogram or ECG). The study plans to enroll 24 adults with Down syndrome, aged 18 or older, who are medically stable. To join, you must have a confirmed diagnosis of Down syndrome and a caregiver who can provide information about your health.

Study design

This interventional study is testing three different increasing doses of MIB-626 against a placebo in 24 adults with Down syndrome.

What's involved

Participants will take MIB-626 or placebo daily for 28 consecutive days. They will be monitored for adverse events and have laboratory tests, including blood counts, chemistries, coagulation profile, and ECGs.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for adverse events for up to 56 days after their last dose of the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.